Gujarat Themis Biosyn Ltd

Gland Pharma maintains a strong capital structure with a debt-to-equity ratio of 0.12, indicating a conservative leverage position relative to its equity base. The company's liquidity is assessed as medium, with a current ratio of 2.53, suggesting it can cover its short-term obligations but with limited excess capacity. However, the company's free cash flow is negative at -635.4 million INR, and capital expenditures are substantial at -1.16 billion INR, indicating significant reinvestment in operations. This capital intensity may impact near-term liquidity flexibility.

Profitability metrics show a return on equity (ROE) of 19.64% and a return on assets (ROA) of 16.19%, both exceeding the typical thresholds for pharmaceutical firms, which are often in the 10-15% range for ROE and 5-10% for ROA. The company's operating margin is 42.16% (635.9 million INR operating income on 1.51 billion INR revenue), and net margin is 32.33% (487.7 million INR net income), both of which are robust and suggest strong cost control and pricing power.

Geographically, Gland Pharma's revenue is concentrated in India, with no disclosed international revenue segments in the latest financials. The company operates in a single business segment focused on injectable and oral solid dosage drugs, with no material diversification across product lines or geographic regions. This concentration may expose the company to regulatory and macroeconomic risks specific to India.

The company's growth trajectory is mixed. Revenue for the latest period is 1.51 billion INR, but no year-over-year growth rate is provided. The outlook for the current fiscal year is neutral, with no significant revenue growth expected. The next fiscal year is projected to show modest improvement, but the exact numeric delta is not disclosed. The capital expenditure of -1.16 billion INR suggests the company is investing in capacity expansion or modernization, which may support future growth but at the expense of near-term cash flow.

Risk factors include medium liquidity risk due to negative free cash flow and high capital expenditures. The company's dilution risk is assessed as low, with no near-term pressure expected. However, the risk assessment notes that net cash is negative after subtracting total debt, which could limit financial flexibility. No recent filings or transcripts are available to provide additional context on strategic or operational developments.

Recent events are not disclosed in the available data, and no material changes in business strategy or regulatory environment are reported. The company's risk profile remains stable, with no significant new risks identified in the latest financial or regulatory filings.